It’s nearing closing time at JP Morgan 2016. And the conference – born of life science companies and their investors – is largely talking tech.
#jpm16 probably the first year that digital health was hotter/better than biotech.
— Brian Neman (@bneman) January 14, 2016
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
How did tech get so hot when the deals in biotech are so much bigger? Maybe it’s the mixed messages of a tighter fund-raising environment for biotech startups – or is it an era of new money and high valuations?
Also, you can credit (or blame) the beating biotech stocks took this week, the announcement by Andy Slavitt about Meaningful Use, other federal pronouncements and the digital health events that now orbit JPM.
But, judging from some of the headlines, this will be the year digital health really has to live up to the hype.
“People were willing up until August of last year to take a high-flier,” or volatile stock, said Dave Francis, an analyst at RBC Capital Markets, who spoke at Health 2.0’s WinterTech conference, which was running concurrently with JP Morgan. “I would argue that if Teladoc were trying to go public today … they would have a very difficult time achieving the valuation that they saw on July 1 of last year.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
JP Morgan is definitely the place to deliver that message.
Gender issues still an issue at JPM? You bet
The Bloomberg story kind of said it all: At Biotech Party, Gender Diversity Means Cocktail Waitresses.
But women at JP Morgan also said it themselves.
Wore black to a #JPM16 event and a man gave me his empty drink glass instead of a business card. https://t.co/KleiHrBREK from @business — Emily Richmond (@emilayamei) January 13, 2016
View from the loo – #jpm16 ladies restroom at @Westin is a great place to hear what women really think about the rush to add them to boards. — Bianca Coulter (@CPBiancaCoulter) January 14, 2016
Enjoy the insight from my colleague at Dealbreaker: Financial Communications Firm Generates “Buzz” At JP Morgan Healthcare Conference With After Party Featuring Real Live Women
Headlines of note
- Pfizer says its CAR T cancer therapy could outshine rivals (Reuters)
- J&J CEO Prefers Smaller Acquisitions Even as Cash Pile Grows (Bloomberg)
- Battling Cancer Comes to the Fore at J.P. Morgan Healthcare Conference (MDDI)
- Valeant Vows to Make Its Drugs ‘Affordable’ (Fortune)
- Express Scripts Plunges as Biggest Client Threatens to Leave (Bloomberg)
- 10X Genomics, Pacific Biosciences Provide Business Updates at JP Morgan Healthcare Conference (GenomeWeb)
Twitterverse
Recurrent theme at #jpm16 & #health2con on #digitalhealth: tech cos must understand the health ecosystem. Not enough to just have good tech.
— Heather Simonsen (@heathersimonsen) January 14, 2016
Sequestration is still unfortunately wreaking havoc as noted by @PaulBegala today at #jpm16. NIH deserves better. pic.twitter.com/Rb4f6zJMxQ
— Zal Bilimoria (@zalzally) January 14, 2016
Dinner speaker pro-tip: reading your sales pitch is not thought leadership #jpm16 — coppedge (@coppedge) January 14, 2016
On redeye home following crazy #JPM16, I stopped off in DC for a quick presser…some points need emphasis #nosleep pic.twitter.com/zYsPXooFkc
— Dan Budwick (@DanBudwick) January 14, 2016
Hotel Nikko apparently charging $35/hour per chair for lobby squatters. I’m in the wrong business #JPM16 — Luke Timmerman (@ldtimmerman) January 12, 2016
There a legal distinction between fwd-looking statements & “a tremendous amount” of fwd-looking statements? https://t.co/gtPp44MABO #JPM16
— cwsampson (@cwsampson) January 14, 2016
Key takeaway from #jpm16 & #wintertech ?? There will (is) blood in the #digitalhealth & ‘innovation spacer’ writ large. Yet Genie out! — Gregg Masters (@2healthguru) January 14, 2016
On last leg of #jpm16 – pretty exhausted – nevertheless energised by some of the stories I heard about progress in #pharma #biotech #medtech
— Mike Ward (@ScripMikeWard) January 14, 2016
Photo: Flickr user Wally Gobetz
